(BGNE) -N/A(N/A%) February 27, 2025 USDNasdaq Global SelectDelayed PriceMarket Closed Earnings Consensus data is not available for symbol. Created with Highcharts 5.0.7Quarter End$ EPS# Estimates$ EPS Actual$ EPS Estimate# Estimates
1、Metsera:半年融资5亿美元的减肥药物公司 11月13日,Metsera宣布完成2.15亿美元的B轮融资,本轮融资由Wellington Management和Venrock Healthcare共同领投,Fidelity、Janus Henderson、T.Rowe Price Associates、Viking Global Investors、Deep Track、RA Capital、ARCH Venture、Alpha Wave、GV、SoftBank Vision Fund 2、...
Goldman Sachs analyst revisits Rivian stock price target after Q4 earnings Rivian's R2 SUV, which is expected to challenge Tesla's Model Y, will launch early next year. RIVN Latest Commodity Market News Feb 20, 2025 4:37 PM EST
BeiGene's stock price reached a new 52-week high of $215.00 on September 11, 2024[2]. The stock has traded between $126.97 and $215.00 over the past 52 weeks[5]. ### Wall Street Analysts Bullish on BGNE According to a recent report from Zacks, Wall Street analysts see a 27.84% up...
Other Consideration for investing in BGNE Stock If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may requ...
quotes Price Overview Performance Report charts Interactive Chart Snapshot Chart technicals Barchart Opinion Trading Strategies Top Trade Alerts Technical Analysis Trader's Cheat Sheet Seasonal Returns Price History Historical Data company News & Headlines Key Statistics SEC Filings Stock Comparison Insider ...
valuation given Co.’s BD capability (cash-rich position of USD4.3bn in YE22E and proven track records) and potential global M&A recovery in 2H22E to help restore market sentiment. Investment risks: clinical delay/failure, lower- than-expected sales, regulatory risks, NRDL-driven price cut ...
Initiate at BUY with TP of US$248.52. We expect zanubrutinib and tislelizumab will continue to be major revenue drivers in coming years. We derive our target price of US$248.52 based on a DCF valuation (WACC: 9.20%, terminal growth rate: 3.0%). ...
we expect the Company to expand tislelizumab’s NRDL coverage via simplified renewal procedures with a relatively small price cut to add four additional indications (1L NPC, 2L ESCC, 2L NSCLC, MSI-H/dMMR solid tumors). The sBLA of 1L GC and 1L ESCC is under review by CDE, and the ...
MCU Renesas Manufacturer Renesas(https://www.renesas.com/) Stock and price Renesas Electronics Corporation IC MCU 32BIT 256KB FLASH 48HWQFN DigiKey R5F51406BGNE-30 767 In Stock Qty :416 units Unit Price : $2.73757 BuyNow Related datasheet ...